Latest From Agennix AG
At an extraordinary general meeting (EGM) on 22 May, Agennix shareholders voted in favor of the liquidation of the company. It will be dissolved by 31 May 2013, with liquidation slated to take at least a year following dissolution.
Agennix, which has looked doomed since the failure of its only significant asset last year, is considering two options ahead of an extraordinary general meeting (EGM) on 22 May 2013. It will ask shareholders to vote on two proposals: a 20:1 reverse stock split and liquidiation of the company.
It's not easy to raise large sums of cash for biotech drug development these days, so having software billionaire Dietmar Hopp on side is an enviable position to be in. And despite the recent blow to his portfolio dealt by the late-stage failure of Agennix's talactoferrin (scripintelligence.com, 7 August 2012), his commitment to biotech is "unwavering", according to one of the key curators of his biotech portfolio, Dr Friedrich von Bohlen. Today's announcement by CureVac would appear to demonstrate this.
The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- Wound Healing & Tissue Repair
- Agennix Inc.
- Western Europe
- Parent & Subsidiaries
- Agennix AG
- Senior Management
Torsten Hombeck, PhD, CFO
Jill Porter, PhD, SVP, Pharmaceutical Dev.
- Contact Info
Phone: (49) 89 85 65 2600
Im Neuenheimer Feld 515
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.